PriceTargets.com logo

Finch Therapeutics Group - FNCH Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.24 As of 04/19/2024 01:00 AM ET
▼ -0.12 (-5.08%)

This chart shows the closing price for FNCH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Finch Therapeutics Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FNCH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FNCH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Finch Therapeutics Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.24.

This chart shows the closing price for FNCH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Finch Therapeutics Group. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2023HC WainwrightLower Target$510.00 ➝ $210.00Low
8/9/2022HC WainwrightInitiated CoverageBuy$510.00Low
4/4/2022Jefferies Financial GroupLower TargetBuy$870.00 ➝ $510.00High
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$870.00High
4/13/2021Evercore ISIInitiated CoverageOutperform$1,020.00Low
4/13/2021Bank of AmericaInitiated CoverageBuy$750.00Low
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.99 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Finch Therapeutics Group logo
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Read More

Today's Range

Now: $2.24
Low: $2.16
High: $2.29

50 Day Range

MA: $2.53
Low: $2.08
High: $3.42

52 Week Range

Now: $2.24
Low: $1.86
High: $16.74

Volume

29,863 shs

Average Volume

54,152 shs

Market Capitalization

$3.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Finch Therapeutics Group?

The following Wall Street sell-side analysts have issued stock ratings on Finch Therapeutics Group in the last year:
View the latest analyst ratings for FNCH.

What is the current price target for Finch Therapeutics Group?

0 Wall Street analysts have set twelve-month price targets for Finch Therapeutics Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Finch Therapeutics Group in the next year.
View the latest price targets for FNCH.

What is the current consensus analyst rating for Finch Therapeutics Group?

Finch Therapeutics Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FNCH.

What other companies compete with Finch Therapeutics Group?

Other companies that are similar to Finch Therapeutics Group include Palisade Bio, Fresh Tracks Therapeutics, 22nd Century Group, TRACON Pharmaceuticals and NanoString Technologies. Learn More about companies similar to Finch Therapeutics Group.

How do I contact Finch Therapeutics Group's investor relations team?

The company's listed phone number is 617-229-6499 and its investor relations email address is [email protected]. The official website for Finch Therapeutics Group is www.finchtherapeutics.com. Learn More about contacing Finch Therapeutics Group investor relations.